Envoy Medical Nears Full Enrollment in Pivotal Acclaim Cochlear Implant Trial

Reuters
02/17
Envoy Medical Nears Full Enrollment in Pivotal Acclaim Cochlear Implant Trial

Envoy Medical Inc. has announced continued progress in enrollment for its pivotal clinical trial of the fully implanted Acclaim® cochlear implant. To date, 45 out of a planned 56 patients have been implanted and enrolled, with full enrollment expected by the end of March 2026. The company anticipates completing the trial and potentially submitting for Premarket Approval (PMA) to the U.S. FDA in the second quarter of 2027. Envoy Medical expects to provide an update on the trial at an industry meeting in May 2026. Results from the study have not yet been formally presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envoy Medical Inc. published the original content used to generate this news brief on February 17, 2026, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10